About Dev Drugs (India) Private Limited
Data last updated:
Dev Drugs (India) Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 October 1996 and has been in existence for over 30 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U65929DL1996PTC082829. Its GSTIN is 05AABCD8818M2ZC (Uttarakhand). The company holds 3 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹16.02 Lakh. It was formerly known as Noni Gopal Infinlease Private Limited. It is led by directors Subrata Roy and Balbir Singh.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 67 Pandav Nagar Patparganj, New Delhi, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹94.58 Lakh, a growth of 32% compared to the previous year. For the same year it recorded a net profit of ₹1,577 (net margin 0%) and EBITDA of ₹28.12 Lakh (EBITDA margin 29.7%). Revenue has declined at a compounded annual rate (CAGR) of 15% over three years and 13% over five years.
The company has about 7 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹8.5 Cr on record. Court records list 1 case involving the company, including 1 filed by the company.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website devdrugs.com.
Company details
Contact details
Dev Drugs (India) Private Limited's registered office is in New Delhi, Delhi. Its website is devdrugs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressD – 67 Pandav Nagar Patparganj, New Delhi, Delhi, India – 110092
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Dev Drugs (India) Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Dev Drugs (India) is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Dev Drugs (India) Private Limited, buy the company report.
Financials of Dev Drugs (India) Private Limited
FY 2025 filings availableDev Drugs (India) Private Limited reported revenue of ₹94.58 Lakh (up 32% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 32% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 13%. EBITDA fell 81% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹28.12 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1,577 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 29.7% | ||||
| Net Profit Margin | 0% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Dev Drugs (India) Private Limited, buy the company report.
Board of directors of Dev Drugs (India) Private Limited
Dev Drugs (India) has 2 current directors and 6 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Subrata Roy Also directs: Dev Pharmacy Private Limited | Director | 14 Sep 2021 | 5 Years 1 Months | Current |
| Balbir Singh | Director | 15 Sep 2020 | 6 Years 1 Months | Current |
Peer comparison
Dev Drugs (India) Private Limited is compared with the 4 companies closest to it by revenue in the Healthcare industry (Alternative Medicine), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Nath Wellness Private Limited | ₹1.41 Cr (FY 2024) | 77.0% | Delhi, India | |||
| Ramakrishna Homeo Pharmaceuticals Private Limited | ₹98.62 Lakh (FY 2023) | 54.0% | Hyderabad, Telangana, India | |||
| Dev Drugs (India) Private Limitedthis company | ₹94.58 Lakh (FY 2025) | ₹1,577 | 0% | 32.0% | 7 | New Delhi, Delhi, India |
| Medilexicon Healthcare India Limited | ₹76.25 Lakh (FY 2024) | -28.0% | Kishangarh, Rajasthan, India | |||
| Hahnemann Pharmaceuticals Private Limited | ₹70.46 Lakh (FY 2024) | 28.0% | New Delhi, Delhi, India |
To see the full peer comparison of Dev Drugs (India) Private Limited, buy the company report.
Auditor
Dev Drugs (India) Private Limited is audited by MB Gupta & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MB Gupta & Co. | FY 2023 | 006928N |
Shareholding
The shareholding of Dev Drugs (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Dev Drugs (India) Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 22 May 2025 | 101100671 | Sidbi | ₹2.55 Cr | Open | |
| 29 Mar 2023 | 100703582 | Sidbi | ₹2.65 Cr | Open | |
| 30 Mar 2022 | 100552164 | Sidbi | ₹2 Cr | Open | |
| 03 Nov 2020 | 100382532 | Sidbi | ₹1.3 Cr | Open |
To see the full charge records of Dev Drugs (India) Private Limited, buy the company report.
Total charge records: 4 View all charges
Legal cases
Dev Drugs (India) Private Limited has 1 court case on record: 1 filed by Dev Drugs (India). All case is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 0 | 0 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gautam Buddha Nagar, Uttar Pradesh | Court case (Complaint Cases) | Filed by the company against Brothers Pharma | Disposed |
To see the full case history of Dev Drugs (India) Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Dev Drugs (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Dev Drugs (India) Private Limited has a workforce of 7 employees on its EPFO records as of Apr 09, 2024, across 1 active EPFO establishment.
GST
Dev Drugs (India) has 3 GST registrations: 2 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AABCD8818M2ZC | Uttarakhand | Active | 13 Jul 2017 |
| 09AABCD8818M1Z5 | Uttar Pradesh | Active | 05 Aug 2017 |
To see the full GST registrations and return filing status of Dev Drugs (India) Private Limited, buy the company report.
Recent activity
Dev Drugs (India) Private Limited has 8 board changes on record since 2020: 2 appointments and 6 cessations. The latest: Subrata Roy ceased to be Additional Director on 30 Nov 2021.
4 earlier events are in the company report.
Frequently asked questions
Dev Drugs (India) is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 October 1996 (30+ years old) and is registered under CIN U65929DL1996PTC082829.
Dev Drugs (India) has 2 current directors:
- Subrata Roy - Director
- Balbir Singh - Director
The latest financial statements of Dev Drugs (India) on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Dev Drugs (India) is 05AABCD8818M2ZC, registered in Uttarakhand. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 09AABCD8818M1Z5 (Uttar Pradesh).
The CIN (Corporate Identification Number) of Dev Drugs (India) is U65929DL1996PTC082829. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Dev Drugs (India) has 1 court case on record: 1 filed by the company.
Dev Drugs (India) was incorporated on 23 October 1996, making it 30+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Dev Drugs (India) by revenue are Nath Wellness Private Limited, Ramakrishna Homeo Pharmaceuticals Private Limited, Medilexicon Healthcare India Limited, Hahnemann Pharmaceuticals Private Limited, all in the Healthcare industry (Alternative Medicine), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Subrata Roy ceased to be Additional Director on 30 Nov 2021. Mitali Roy ceased to be Additional Director on 14 Sep 2021. Subrata Roy was appointed as Director on 14 Sep 2021. Dev Drugs (India) has 8 board changes on record in total.
Dev Drugs (India) can be reached through the website devdrugs.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Dev Drugs (India) is at D – 67 Pandav Nagar Patparganj, New Delhi, Delhi, India – 110092.